Immunic (IMUX) News Today

Immunic, Inc. (NASDAQ: IMUX) is receiving a generally favorable signal from updated analyst earnings forecasts, although estimates remain mixed and the company is still expected to report losses in the near term.

• Positive Sentiment: HC Wainwright substantially improved its long-term outlook. The firm raised its EPS forecasts for 2026 through 2030, including reducing projected 2026 losses to $3.18 per share from $7.02 and projecting positive $0.40 EPS in 2030, versus a previous loss estimate of $2.92. HC Wainwright maintained a Buy rating and a $22 price target, supporting the view that Immunic’s pipeline could move the company toward profitability. Analysts Offer Insights on Healthcare Companies: Krystal Biotech and Immunic
• Positive Sentiment: HC Wainwright also raised its third- and fourth-quarter 2026 EPS estimates to losses of $0.74 and $0.68, respectively, from losses of $2.21 and $2.03. Brookline Capital Markets likewise improved its 2026 forecast to a $3.86-per-share loss from $4.34 and raised its third-quarter estimate to a $0.84-per-share loss from $1.07. These revisions suggest analysts expect lower operating losses than previously anticipated.
• Neutral Sentiment: Analyst sentiment is not unanimous. Wall Street Zen upgraded Immunic to “Hold,” while Brookline maintains more cautious estimates, including a slightly wider fourth-quarter 2026 loss forecast of $1.16 per share. The differing views could limit the positive impact of HC Wainwright’s revisions. Immunic Raised to Hold at Wall Street Zen
• Negative Sentiment: Despite the improved forecasts, Immunic remains unprofitable, with the broader consensus calling for a $4.49-per-share loss in the current fiscal year. As a development-stage biotechnology company, IMUX remains dependent on clinical and regulatory progress, so the stock may remain volatile even as longer-term earnings expectations improve.